IC17 Parkinson's Disease Flashcards

(46 cards)

1
Q

What are the 4 characterpstic features of PD (which ones are cardinal signs)?

A
  1. Tremors (resting)
  2. Rigidity (lead pipe or cogwheel)
  3. Akinesia (bradykinesia)
  4. Postural instability
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How do tremors manifest and what should be excluded?

A

resting tremors that disappear with movement and increases with stress

exclude generalised anxiety that can be triggered by certain activities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What must be present for a PD diagnosis?

A

Clinical signs, physical exam and history

2/3 of the cardinal signs (T,R,A)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the characteristic features of idiopathic PD? Which ones manifest upon diagnosis and which ones show up later on?

A

Upon dx:
assymetry

Later on:
positive response to levodopa or apomorphine
less rapid progression
may present with impaired olfaction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the possible factors that could lead to loss of dopaminergic neurons in PD? (3)

A

age-related factors

environmental toxins or insults (MPTP-MPP+, pesticides, herbicides)

genetic factors (predisposition to toxins or insults and genetic abnormalities)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Which 2 scoring systems can be used used for PD staging?

A

Hoehn and Yahr (H&Y)
MDS-UPDRS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the 5 non-motor symptoms of PD?

A
  1. Cognitive impairment → dementia
  2. Psychiatric symptoms → depression, psychosis
  3. Sleep disorders → REM sleep behaviour disorder
  4. Autonomic dysfunction → constipation, GI motility, sialorrhea and orthostatic hypotension
  5. Other symptoms → fatigue
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Differentiate between the features in early onset PD and typical PD? (3)

A

slower disease progression
less cognitive decline
earlier motor complications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the 2 goals of therapy for PD?

A

manage symptoms
maintain function and autonomy

no neuroprotective treatment yet

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Which 2 symptoms of PD are levodopa good for managing?

A

rigidity and akinesia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is an important counselling point for taking levodopa?

A

Space apart from heavy meal

If got n&v, can take w light snacks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the DCI dosing required to saturate DOPA?

A

75-100mg daily

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the levodopa to DCI ratios?

A

Sinemet 1:4 or 1:10
Madopar 1:4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the side effects of levodopa (5)

A
  1. nausea, vomiting (especially in new treatment)
  2. orthostatic hypotension
  3. drowsiness and sudden sleep onset
  4. hallucinations, psychosis
  5. dyskinesias (usual onset 3-5 years of starting levodopa)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the “on-off” phenomenon in levodopa treatment?

A

ON refers to levodopa response
OFF refers to no levodopa response

unpredictable and not related to dose or dosing intervals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the “wearing off” phenomenon in levodopa treatment?

A

effect of levodopa wanes before the end of the dosing interval with a shortened ON time, associated with disease progression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

How can “wearing off” be managed?

A

modifying times of administration or replacing with modified-release preparations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

How can peak dose dyskinesia be managed?

A

manage by decreasing dose and increasing frequency

alternatively can be managed by adding amantadine or replacing levodopa with specific doses or MR-levodopa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

How should dose of levodopa/DCI be adjusted with switching from IR to CR form?

A

Increase dose by 25-50%

20
Q

What are the DDIs with levodopa?

A
  1. Pyridoxine (vitamin B) → cofactor for DOPA decarboxylase, possibility of interactions with high dose B6
  2. Iron → space out administration
  3. Protein → space out administration
  4. Dopamine antagonists → such as risperidone, FGA and metoclopramide/prochlorperazine (domperidone is antiemetic of choice in PD)
21
Q

What dosage forms are rotigotine and apomorphine available in

A

rotigotine: transdermal patch
apomorphine: SC injection

22
Q

What are the peripheral dopaminergic side effects of dopamine agonists?

A

Dopaminergic (peripehral) → nausea, vomiting, orthostatic hypotension, leg edema

23
Q

What are the central dopaminergic side effects of dopamine agonists?

A

Dopaminergic (central) → hallucinations (visual > auditory), somnolence, day-time sleepiness, compulsive behaviours (gambling, shopping, eating, hypersexuality)

24
Q

What are the non-dopaminergic side effects of dopamine agonists?

A

Non-dopaminergic → fibrosis, valvular heart disease

25
Compare between the efficacy and side effect profile of dopamine agonists and levodopa
Dopamine agonists result in less motor complications than levodopa but shows a higher instance of hallucinations, sleep dsiturbances, eg. edema and orthostatic hypotension
26
What is the place in therapy for dopamine agonists
Monotherapy in young-onset PD Adjunct to levodopa in moderate to severe PD
27
Which two dopamine agonists are available as both IR and SR forms?
Pramipexole and Ropinorole
28
Which neurotransmitters do MAO-A and MAO-B act on
MAO-A (peripheral) → NA and 5-HT MAO-B (central) → DA
29
What type of drugs are selegiline and rasagiline?
irreversible MAO-B inhibitors
30
Describe the half life and duration of action for selegiline and rasagiline
Short half-life of 1.5-4h Long duration of action due to irreversibility
31
When are MAO-B inhibitors indicated in PD treatment?
Early stages of disease Can use as monotherapy
32
How should selegiline be dosed
0.5mg OM to BD second dose in the afternoon because metabolite (amphetamine) is stimulating
33
How should rasagiline be dosed
0.5 to 2mg OD
34
What are DDIs with MAO-B inhibitors?
SSRIs, SNRIs, TCAs (washout period recommended for these 3) pethidine, tramadol, linezolid, dextrometorphan, dopamine, sympathomimetics (eg. nasal decongestants like pseudoephedrine and phenylephrine) and other MAOis
35
What are COMTi drugs
Entacapone Tolcapone (not used anymore due to ADRs)
36
How do COMTi drugs help in PD?
They help to decrease “off” time
37
How should COMTi drugs be administered?
At the same time as levodopa (not effective as monotherapy)
38
What kind of a COMTi is entacapone
Reversible
39
What are DDIs with COMTis?
1. iron, calcium 2. concurrent nonselective MAOi (but safe w MAOBi) 3. any catecholamine drug 4. warfarin (enhances anticoagulant effect)
40
What are side effects of COMTis? (3)
diarrhea urine discolouration (orange) may cause dyskinesia and potentiate other dopaminergic effects (ortho hypotension, n&v)
41
In which populations should entacapone be used with caution?
Pts w hepatic impairment
42
What symptoms do anticholinergics help with
Tremors
43
What are the side effects of NMDA antagonists? (6)
nausea, light-headedness, insomnia, confusion, hallucinations, livedo reticularis
44
What is memantine's place in PD therapy?
Mostly adjunctive to manage levodopa-induced dyskinesia
45
What are the features of drug-induced parkinsonism
symptoms tend to occur bilaterally drug withdrawal usually leads to sx improvement
46
What are high risk drugs that can cause drug-induced parkinsonism?
1. Dopamine receptor blockers → typical antipsychotics (eg. haloepridol, prochlorperazine), high dose atypical antipsychotics (eg. risperidone, olanzapine, aripiprazole) 2. Dopamine depleters 3. Dopamine synthesis blockers → α-methyldopa